{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T07:42:25.413626+00:00","company":{"ticker":"ONC","cik":1651308,"company_name":"BeOne Medicines Ltd."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"431abc8f8c93008e588fe3daaddc75d1e27408bd","cik":1651308,"ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"GAAP diluted EPS per ADS $1.96","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"GAAP net income $227,357","period_text":"the three months ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"Total revenue $1,513,438"},"claim":"BeOne Medicines Ltd. reported the three months ended March 31, 2026 results: revenue Total revenue $1,513,438, net income GAAP net income $227,357, EPS GAAP diluted EPS per ADS $1.96.","evidence_excerpt":"U.S. dollars and unaudited) Three Months Ended March 31, 2026 2025 % Change Net product revenues $ 1,487,329 $ 1,108,530 34 % Other revenue $ 26,109 $ 8,749 198 % Total revenue $ 1,513,438 $ 1,117,279 35 % GAAP income from operations $ 249,902 $ 11,102 2,151 % Adjusted income from operations* $ 414,394 $ 139,357 197 % GAAP net income $ 227,357 $ 1,270 17,802 %","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-030866","anchor_url":"https://secwatch.observer/filing/0001628280-26-030866#claim-431abc8f8c93008e588fe3daaddc75d1e27408bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026030866/0001628280-26-030866-index.htm"},{"fact_type":"debt_financing","fact_key":"4f5e12580082d21316144ad8e58eafc93f6dbf97","cik":1651308,"ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2025-08-25T23:59:59+00:00","payload":{"counterparty":"Royalty Pharma Investments 2023 ICAV","effective_date":"2025-08-25","event":"incurrence","instrument_type":"other","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli","principal_text":"$885 million upfront payment, with option for up to $65 million additional"},"claim":"BeOne Medicines Ltd. incurred debt of $885 million upfront payment, with option for up to $65 million additional with Royalty Pharma Investments 2023 ICAV maturing sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli.","evidence_excerpt":"(the “Company”), BeOne Medicines I GmbH (the “Seller”), a subsidiary of the Company, and Royalty Pharma Investments 2023 ICAV (“Royalty Pharma”) entered into a Royalty Purchase Agreement (the “Royalty Purchase Agreement”).","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001628280-25-041082","anchor_url":"https://secwatch.observer/filing/0001628280-25-041082#claim-4f5e12580082d21316144ad8e58eafc93f6dbf97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1651308/000162828025041082/0001628280-25-041082-index.htm"},{"fact_type":"executive_change","fact_key":"c7534be81a","cik":1651308,"ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2024-09-26T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-27","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Shalini Sharp was appointed as Director at BeOne Medicines Ltd..","evidence_excerpt":"appointed Shalini Sharp to the Board to fill the vacancy, effective September 27, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001651308-24-000118","anchor_url":"https://secwatch.observer/filing/0001651308-24-000118#claim-c7534be81a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000118/0001651308-24-000118-index.htm"},{"fact_type":"executive_change","fact_key":"909b727021","cik":1651308,"ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2024-07-18T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-19","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Aaron Rosenberg","successor_named":true},"claim":"Julia Wang resigned as Chief Financial Officer at BeOne Medicines Ltd..","evidence_excerpt":"On July 17, 2024, Julia Wang, the Company’s current CFO, resigned as CFO effective July 19, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001651308-24-000086","anchor_url":"https://secwatch.observer/filing/0001651308-24-000086#claim-909b727021","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000086/0001651308-24-000086-index.htm"},{"fact_type":"executive_change","fact_key":"7b820cc17d","cik":1651308,"ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2024-07-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-22","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Aaron Rosenberg was appointed as Chief Financial Officer at BeOne Medicines Ltd..","evidence_excerpt":"On July 18, 2024, BeiGene, Ltd. (the “Company”) announced the appointment of Aaron Rosenberg as the Chief Financial Officer (“CFO”) and the principal financial officer of the Company, effective as of July 22, 2024 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001651308-24-000086","anchor_url":"https://secwatch.observer/filing/0001651308-24-000086#claim-7b820cc17d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000086/0001651308-24-000086-index.htm"},{"fact_type":"earnings_release","fact_key":"9756978984f49794f848fe59dcc51d17f6575eea","cik":1651308,"ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$752 million"},"claim":"BeOne Medicines Ltd. reported the three months ended March 31, 2024 results: revenue $752 million.","evidence_excerpt":"as Exhibit 99.1 to this Current Report on Form 8-K. \n\n--- EX-99.1 (EX-99.1) ---\n\nBeiGene Reports First Quarter 2024 Financial Results and Business Updates • Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period • BRUKINSA revenue of $489 million, driven by growth in the U.S. and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001651308-24-000049","anchor_url":"https://secwatch.observer/filing/0001651308-24-000049#claim-9756978984f49794f848fe59dcc51d17f6575eea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/0001651308-24-000049-index.htm"},{"fact_type":"executive_change","fact_key":"fa9791be93","cik":1651308,"ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2024-03-20T23:59:59+00:00","payload":{"action":"stepped down as principal accounting officer","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-03-19","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Titus Ball","successor_named":true},"claim":"Julia Wang changed role as Chief Financial Officer at BeOne Medicines Ltd..","evidence_excerpt":"Mr. Ball assumes the role of principal accounting officer from Julia Wang, the Company’s Chief Financial Officer, who previously served as the Company’s principal financial officer and principal accounting officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001651308-24-000032","anchor_url":"https://secwatch.observer/filing/0001651308-24-000032#claim-fa9791be93","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000032/0001651308-24-000032-index.htm"},{"fact_type":"earnings_release","fact_key":"2d51b76b5b1106b03e89d3df1f49976867592849","cik":1651308,"ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"three months and year ended December 31, 2023","report_date":"2024-02-26","result_type":"reported_results","revenue_text":"$634.4 million and $2.5 billion"},"claim":"BeOne Medicines Ltd. reported three months and year ended December 31, 2023 results: revenue $634.4 million and $2.5 billion.","evidence_excerpt":"EX-99.1 (EX-99.1) ---\n\nBeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates • Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods • Strengthened leadership in hematology with global BRUKINSA®","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001651308-24-000011","anchor_url":"https://secwatch.observer/filing/0001651308-24-000011#claim-2d51b76b5b1106b03e89d3df1f49976867592849","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/0001651308-24-000011-index.htm"}]}